For research use only. Not for human or animal consumption.
What it is
Epithalon — also written Epitalon or Epithalone — is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, abbreviated AEDG. It was composed on the basis of the amino-acid composition of Epithalamin, a bovine pineal gland polypeptide extract. The 2025 International Journal of Molecular Sciences review states that origin explicitly [2]. The extract and the four-residue synthetic peptide are related; they are not the same material, and that distinction does more work in this compound’s literature than it does for almost any other peptide in circulation.
The identity a genuine vial should match:
- Chemical name: Epithalon (Epitalon, AEDG tetrapeptide)
- Sequence: Ala-Glu-Asp-Gly
- CAS number: 307297-39-8
- Molecular formula: C14H22N4O9
- Molecular weight: 390.35
- Form: lyophilised (freeze-dried) powder
- Storage: −20 °C, desiccated, protected from light
Structurally the molecule is unusual. Four residues. Three free carboxyl groups — on Glu, on Asp, and at the C-terminal Gly — plus one free N-terminal amine. No tryptophan, no tyrosine, no phenylalanine; no ring system anywhere in the molecule. Every analytical quirk below follows from those two facts: it is very small, and it is net-acidic with no aromatic ring.
What researchers have measured
Everything below is preclinical — cell culture, rodent, or computational. None of it establishes an effect in a person, and none of it is written here as one. Each entry names the group, the model system, the assay and the endpoint, in the past tense; none of it is carried forward as a property of the material.
Telomere assays in cell culture are the largest theme in the published record. In the foundational 2003 report from the originating institute, investigators added the peptide to telomerase-negative human fetal fibroblast cultures and assayed three endpoints: expression of the telomerase catalytic subunit, telomerase enzymatic activity, and telomere length [6]. A 2025 group at Brunel University London revisited the question quantitatively, assaying telomere length, hTERT mRNA expression, telomerase enzyme activity and alternative lengthening of telomeres (ALT) activity by qPCR and immunofluorescence across two breast-carcinoma-derived lines, 21NT and BT474, alongside normal epithelial and fibroblast cells [1]. The authors report ALT activation appearing specific to the carcinoma-derived lines, and state that the work is in vitro and requires animal-model validation. That paper carries a published erratum, listed with the reference.
Rodent endpoints across a full life course. A 2003 study followed 108 female outbred Swiss-derived SHR mice, 54 per group, from three months of age until natural death; one group received the tetrapeptide on the schedule and at the amounts described in the paper, the other received saline. Recorded endpoints were body weight, food consumption, mean and maximum survival time, age-related change in oestrous cyclicity, frequency of chromosome aberrations in bone-marrow cells, and spontaneous tumour incidence. The abstract reports no change in food consumption, body weight or mean survival time, and no change in total spontaneous tumour incidence [3].
Tumour endpoints in a transgenic strain. A 2002 study in female FVB/N HER-2/neu transgenic mice compared saline, the AEDG tetrapeptide, and the dipeptide Vilon (Lys-Glu), each given on the schedule and at the amounts described in the paper, and recorded cumulative tumour number and size, lung metastases, and HER-2/neu mRNA expression. The two peptides moved several endpoints in opposite directions, which the authors report explicitly [4].
Differentiation markers in stem-cell culture. A 2020 study assayed expression of four neurogenic differentiation marker genes — Nestin, GAP43, beta-Tubulin III and Doublecortin — and synthesis of the corresponding proteins in human gingival mesenchymal stem-cell culture, paired with molecular modelling of peptide binding to histones H1/3 and H1/6 at DNA-interacting sequence sites as a candidate epigenetic mechanism [5].
Where the evidence stops
The literature is real, and it is narrow. A PubMed search for “epitalon OR epithalon” returns 142 records (retrieved 2026-08-20) — a small body for a compound in circulation since 2000 — and much of it originates from the St. Petersburg Institute of Bioregulation and Gerontology, the group that created the peptide, or from its collaborators. Independent replication outside that lineage is sparse; the 2025 Brunel work [1] is one of the few. Exactly one PubMed record for the compound carries a clinical-trial publication type, and none carries a randomised-controlled-trial type. The 2025 review notes that physico-chemical and structural investigation of the peptide itself remains limited relative to the volume of biological work [2].
Compound identity muddies it further. PubMed indexes roughly 102 records under “epithalamin”, the bovine extract, against 142 under epitalon/epithalon, the synthetic tetrapeptide, and secondary and commercial writing routinely merges the two. A reader who meets “the human studies” in vendor copy usually cannot tell which of the two materials was used.
How to verify a vial of epithalon before you pay
Three checks apply to any research peptide, and four more are specific to a molecule this small.
- A named third-party laboratory. The certificate should name an outside lab, not the seller’s own bench. Clarion’s current Epithalon lot is analysed by Freedom Diagnostics Testing; the catalogue also uses Janoshik Analytical, and the laboratory is resolved per lot from that lot’s own certificate rather than assumed across the catalogue.
- A lot number that matches the vial. A certificate for a different batch says nothing about the vial in hand. Clarion publishes a public lot ledger where a lot number resolves to that lot’s own signed certificate.
- A printed method and figure, not the word “tested.” Purity by HPLC main peak — Clarion’s published release specification is >99% — and identity confirmed by mass spectrometry, with the numbers on the page.
Then the small-peptide specifics:
- Check the HPLC detection wavelength. AEDG has no aromatic residue, so it has essentially no absorbance at 280 nm and has to be detected near 214–220 nm via the peptide bond itself. A chromatogram run at 280 nm is not measuring this molecule.
- Check the retention time and column. With three free carboxyls and one free amine, the peptide is strongly hydrophilic and elutes near the void volume on a standard C18 reversed-phase gradient — exactly where salts, residual solvent and small impurities also elute. For this compound the column chemistry, gradient and retention time carry more information than the main-peak percentage does.
- Read what the mass spectrum actually proves. Mass confirms mass, not sequence, and at four residues the mass is weakly diagnostic. Every permutation of Ala-Glu-Asp-Gly is isobaric with AEDG, and the Ala + Asp residue pair is isobaric with the Gly + Glu pair — both 186.064 — so certain composition substitutions land on the same monoisotopic mass too. An [M+H]+ near 391 alone does not establish sequence. MS/MS sequencing, or co-elution against a reference standard, is what distinguishes correct AEDG from a scrambled or substituted analogue.
- Ask whether the milligram figure is net peptide content. AEDG is net-acidic, so the “subtract 10–20% for TFA counterions” heuristic carried over from basic peptides does not transfer. Acidic peptides may be lyophilised as the free acid or as a salt, with or without bulking agent, and the dry cake looks identical either way. Only the certificate can say whether a stated figure is net peptide or gross fill weight.
One arithmetic note, because it distorts price comparison. Ten milligrams of a 390-dalton tetrapeptide is about 25.6 micromoles; ten milligrams of a 3,000-dalton peptide is about 3.3 micromoles. Roughly an eightfold difference in molar amount sits behind an identical “10 mg” on two labels, which makes cross-compound price-per-milligram comparisons close to meaningless here.
All of the above can be run against Clarion’s public lot ledger, the certificate linked from the [Epithalon product page](https://clarionpeptides.## Common questions
What is Epitalon, in one line? A synthetic four-amino-acid peptide, Ala-Glu-Asp-Gly, CAS 307297-39-8, molecular weight 390.35, supplied as a lyophilised powder for research use only.
Is Epitalon the same as Epithalamin? No. Epithalamin is a bovine pineal gland polypeptide extract — a mixture. Epitalon is a single synthetic tetrapeptide composed on the basis of that extract’s amino-acid composition [2]. Much of the human-cohort material quoted in commercial copy was generated with the extract.
Why does the detection wavelength matter? The molecule contains no aromatic residue and so has essentially no 280 nm signal. Detection has to be near 214–220 nm.
Does a mass-spectrometry record prove the sequence? Not on its own at this size. Sequence permutations and certain composition substitutions share the same mass; MS/MS or comparison against a reference standard is what separates them.
How should it be stored? At −20 °C, desiccated and protected from light.
Is this a medicine? No. It is a research-use-only material, not for human or animal consumption.
References
Where a paper’s title states an outcome, the title is described rather than reproduced. Authors, journal, year, volume, pages, DOI and PMID are unchanged, so every record can be retrieved and read in full.
- Al-Dulaimi S, Thomas R, Matta S, Roberts T. Biogerontology. 2025 Sep 4;26(5):178. doi:10.1007/s10522-025-10315-x. PMID: 40908429. Erratum in: Biogerontology. 2025 Nov 15;27(1):1. doi:10.1007/s10522-025-10326-8. Subject: in-vitro assays of telomere length, hTERT expression, telomerase activity and ALT activity in human cell lines.
- Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. 2025 Mar 17;26(6):2691. doi:10.3390/ijms26062691. PMID: 40141333.
- Anisimov VN, Khavinson VKh, Popovich IG, et al. Biogerontology. 2003;4(4):193-202. doi:10.1023/a:1025114230714. PMID: 14501183. Subject: a lifetime study in female Swiss-derived SHR mice recording survival, body weight, food consumption, oestrous cyclicity, bone-marrow chromosome aberrations and spontaneous tumour incidence.
- Anisimov VN, Khavinson VK, Provinciali M, et al. Subject: mammary tumour endpoints and HER-2/neu mRNA expression assayed in a HER-2/neu transgenic mouse model — Int J Cancer, 2002 Sep 1;101(1):7-10, doi:10.1002/ijc.10570, PMID: 12209581.
- Khavinson V, Diomede F, Mironova E, et al. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules. 2020 Jan 30;25(3):609. doi:10.3390/molecules25030609. PMID: 32019204.
- Khavinson VKh, Bondarev IE, Butyugov AA. Bull Exp Biol Med. 2003 Jun;135(6):590-2. doi:10.1023/a:1025493705728. PMID: 12937682. Subject: assays of telomerase activity and telomere length in human somatic cells.
Every reference above was retrieved and confirmed against the NCBI PubMed record on 2026-08-19. No other literature is cited on this page, because no other paper was verified for it.
Related: How to verify a peptide certificate of analysis.
Epithalon (Epitalon, AEDG tetrapeptide), CAS 307297-39-8, C14H22N4O9, MW 390.35. Release specification >99% by HPLC main peak, identity confirmed by mass spectrometry; the analysing laboratory and the figures for a given lot are printed on that lot’s own certificate, reachable from the QR code on the vial. For research use only. Not for human or animal consumption. Not a drug.
